AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ANAB
AnaptysBio, Inc. (ANAB) EV/Sales
As of 16 October 2026, AnaptysBio, Inc. (ANAB) trades at a EV/Sales of 4.5×. Over the past ten years it has ranged from −11.7× (November 2019) to 91.0× (March 2018); the current reading is higher than 61% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.6× | — |
| FY2024 | −1.4× | — |
| FY2023 | 0.1× | (99.40%) |
| FY2022 | 10.7× | 650.34% |
| FY2021 | 1.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | −4.9× | — |
| FY2018 | 35.2× | (48.24%) |
| FY2017 | 67.9× | — |
| FY2016 | −0.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 3.3× | 26.42% |
| Dec 2025 | 2.6× | 39.34% |
| Sep 2025 | 1.9× | 43.29% |
| Jun 2025 | 1.3× | 251.41% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RAPP Rapport Therapeutics, Inc. compare | n/m |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| RARE Ultragenyx Pharmaceutical Inc. compare | 1.7× |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 2.5× |
| ANAB AnaptysBio, Inc. | 4.5× |
| KRSA Korsana Biosciences, Inc. compare | 8.8× |
| QURE uniQure N.V. compare | 36.8× |
| ABSI Absci Corporation compare | 704× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)